David Mutch

22PUBLICATIONS
146CO-AUTHORS
Haematological tumoursCancer therapy (excl. chemotherapy and radiation therapy)Predictive and prognostic markersMolecular targetsCancer genetics
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (22)

|Sep 28, 2026
Germline homologous recombination deficiency influences TP53-mutant clonal hematopoiesis fitness during platinum and PARP inhibitor treatment.

|Aug 29, 2026
The new (version 9) American Joint Committee on Cancer (AJCC) tumor-node-metastasis (TNM) staging protocol for carcinoma of the vulva.

|Jul 22, 2025
Multiomic Characterization of Pre- and Post-Neoadjuvant Chemotherapy-Treated Ovarian Cancer Reveals Mediators of Tumorigenesis and Chemotherapy Response.

Mark C Valentine, Mary M Mullen, Emilee N Kotnik

|Feb 26, 2025
Enhancing Progestin Therapy with a Glucagon-Like Peptide 1 Agonist for the Conservative Management of Endometrial Cancer.

Andrea R Hagemann, Ian S Hagemann, David G Mutch

|Dec 19, 2024
Long-Term Follow-Up and Overall Survival in NRG258, a Randomized Phase III Trial of Chemoradiation Versus Chemotherapy for Locally Advanced Endometrial Carcinoma.

Daniela E Matei, Danielle M Enserro, Marcus E Randall

|May 22, 2024
Phase I and Randomized Phase II Study of Ruxolitinib With Frontline Neoadjuvant Therapy in Advanced Ovarian Cancer: An NRG Oncology Group Study.

Charles N Landen, Ronald J Buckanovich, Michael W Sill

Pageof 4

Frequent Collaborators

4 joint publications

Matthew A Powell

4 joint publications

Ian S Hagemann

4 joint publications

Krishnansu S Tewari

3 joint publications

Dineo Khabele